Gilead Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. 

CEO
Daniel P. O'Day
CEODaniel P. O'Day
Employees
17,600
Employees17,600
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
1987
Founded1987
Employees
17,600
Employees17,600

GILD Key Statistics

Market cap
173.36B
Market cap173.36B
Price-Earnings ratio
21.83
Price-Earnings ratio21.83
Dividend yield
2.24%
Dividend yield2.24%
Average volume
8.78M
Average volume8.78M
High today
$140.99
High today$140.99
Low today
$138.69
Low today$138.69
Open price
$140.36
Open price$140.36
Volume
7.32M
Volume7.32M
52 Week high
$141.71
52 Week high$141.71
52 Week low
$93.37
52 Week low$93.37

Stock Snapshot

Gilead Sciences(GILD) stock is priced at $139.72, giving the company a market capitalization of 173.36B. It carries a P/E multiple of 21.83 and pays a dividend yield of 2.2%.

On 2026-01-28, Gilead Sciences(GILD) stock moved within a range of $138.69 to $140.99. With shares now at $139.72, the stock is trading +0.7% above its intraday low and -0.9% below the session's peak.

Trading activity shows a volume of 7.32M, compared to an average daily volume of 8.78M.

The stock's 52-week range extends from a low of $93.37 to a high of $141.71.

The stock's 52-week range extends from a low of $93.37 to a high of $141.71.

GILD News

Simply Wall St 1d
Gilead’s Trodelvy Data Sparks Questions On Valuation And Oncology Growth

Gilead Sciences reported that Trodelvy combined with Keytruda produced significantly improved progression free survival in first line treatment of advanced PD L...

Gilead’s Trodelvy Data Sparks Questions On Valuation And Oncology Growth
Simply Wall St 6d
How Investors May Respond To Gilead Sciences Trodelvy Keytruda Breast Cancer Data In NEJM

Gilead Sciences announced that The New England Journal of Medicine has published full Phase 3 ASCENT-04/KEYNOTE-D19 results, showing Trodelvy plus Keytruda impr...

How Investors May Respond To Gilead Sciences Trodelvy Keytruda Breast Cancer Data In NEJM
Simply Wall St 7d
Gilead Sciences Valuation Check After Trodelvy Keytruda Phase 3 Success And Regulatory Progress

Gilead Sciences (GILD) is back in focus after detailed Phase 3 ASCENT-04/KEYNOTE-D19 results in The New England Journal of Medicine showed that Trodelvy plus Ke...

Gilead Sciences Valuation Check After Trodelvy Keytruda Phase 3 Success And Regulatory Progress

Analyst ratings

76%

of 29 ratings
Buy
75.9%
Hold
24.1%
Sell
0%

People also own

Based on the portfolios of people who own GILD. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.